# Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion

> **NCT07670338** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 308 (estimated)

## Conditions studied

- Malignant Pleural Effusions (Mpe)

## Interventions

- **OTHER:** Treatment with Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage
- **DRUG:** Placebo granules plus chest tube drainage and intrapleural bevacizumab injection

## Key facts

- **NCT ID:** NCT07670338
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670338, "Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*